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Abstract
Androgen deprivation induces the regression of prostate tumors mainly due to an increase in the apoptosis rate;
however, the molecular mechanisms underlying the antiapoptotic actions of androgens are not completely under-
stood. We have studied the antiapoptotic effects of androgens in prostate cancer cells exposed to different pro-
apoptotic stimuli. Terminal deoxynucleotidyl transferase–mediated nick-end labeling and nuclear fragmentation
analyses demonstrated that androgens protect LNCaP prostate cancer cells from apoptosis induced by thapsigar-
gin, the phorbol ester 12-O-tetradecanoyl-13-phorbol-acetate, or UV irradiation. These three stimuli require the ac-
tivation of the c-Jun N-terminal kinase (JNK) pathway to induce apoptosis and in all three cases, androgen
treatment blocks JNK activation. Interestingly, okadaic acid, a phosphatase inhibitor that causes apoptosis in
LNCaP cells, induces JNK activation that is also inhibited by androgens. Actinomycin D, the antiandrogen bicalu-
tamide or specific androgen receptor (AR) knockdown by small interfering RNA all blocked the inhibition of JNK
activation mediated by androgens indicating that this activity requires AR-dependent transcriptional activation.
These data suggest that the crosstalk between AR and JNK pathways may have important implications in prostate
cancer progression and may provide targets for the development of new therapies.
Neoplasia (2008) 10, 418–428
Introduction
Prostate cancer constitutes a major health problem in Western
countries. It has been predicted that in 2007 prostate cancer will be-
come the most common noncutaneous cancer in men [1]. Prostate
tumors are typically androgen dependent during initial stages and are
therefore responsive to androgen deprivation therapy. The removal
of androgens during the initial stages of prostate cancer causes tumor
regression through a combination of reduced cellular proliferation
and increased apoptosis [2–4]. Despite the initial efficacy of andro-
gen deprivation therapy, most prostate cancers progress to androgen-
independent disease at which stage no effective therapy is currently
available [5–7]. The acquisition of resistance to apoptosis that accom-
panies the transition to androgen independence is one of the hallmarks
of advanced prostate cancers [8]. Better understanding of the antiapop-
totic action of androgens and the mechanisms by which prostate can-
cer cells can bypass apoptotic signals are essential for the development
of new strategies in the treatment of advanced prostate cancer.
Androgens exert their effects mainly through binding to androgen
receptor (AR), a member of the nuclear receptor superfamily. Upon
hormone binding, AR translocates into the nucleus where it binds
to specific response elements. A number of co-regulators and/or
co-regulator complexes are recruited to AR, which then control the
transcription of various target genes [9,10]. Many of these AR target
genes are deregulated during the later, “androgen-independent” phase
of prostate cancer [11]. Current data suggest that although prostate
cancer cells become androgen independent, AR is expressed and is
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functional during tumor progression, suggesting an important role
for AR signaling during all phases of prostate carcinogenesis [12,13].
Mitogen-activated protein kinases (MAPKs) are among the most
widely used signal transduction pathways in eukaryotic cells. One of
the main MAPKs, c-Jun N-terminal kinase (JNK, also called stress-
activated protein kinase) is known to play a critical role in different
cellular activities, including cell growth and programmed cell death
(reviewed in Ref. [14]). Similar to other MAPKs, JNK is activated by
sequential protein phosphorylation through a MAPK module [15]
and can be inactivated by the action of specific phosphatases (tyro-
sine, serine/threonine, and the dual-specificity phosphatases) (for a
review, see Ref. [16]). Once activated, JNK phosphorylates and acti-
vates numerous downstream effectors, among them a number of
transcription factors such as c-Jun, the major component of the
AP-1 complex [17].
Crosstalk between these two protein families, nuclear receptors
and MAPKs, has previously been reported. Originally described for
the reciprocal inhibition between the ligand-bound glucocorticoid re-
ceptor (GR) and the activated transcription factor AP-1, this antag-
onism was later shown to exist for different members of the nuclear
receptor superfamily (for reviews, see Refs. [18–20]), including AR
[21,22], for which competition for limiting cofactors in the cell, such
as CBP, has been implicated [22,23]. However, from studies on other
nuclear receptors it is known that there are additional potential mech-
anisms for this crosstalk. For example, the cross-inhibition between
GR and AP-1 may occur through mutual inhibition of DNA binding,
prevention of fruitful interactions with the transcriptional initiation
complex, interference with the JNK signaling pathway, and direct
GR-JNK interactions that cause direct inhibition of JNK pathway ac-
tivation [24–27].
To study the possible interaction between AR and the JNK path-
way we used the androgen-responsive prostate cancer cell line
LNCaP cells. Previous studies carried out in our laboratory demon-
strated that the treatment of LNCaP cells with the phorbol ester 12-
O-tetradecanoyl-13-phorbol-acetate (TPA), an activator of protein
kinase C [28–30], or with thapsigargin (TG), an inhibitor of the
Ca2+ ATPase present in the endoplasmic reticulum [31], induced
JNK activation and concomitant apoptosis [32]. Supporting the in-
volvement of JNK in apoptosis, the specific inhibition of JNK sig-
naling significantly reduced the levels of apoptosis induced by TPA
and TG [32,33].
In this study we demonstrate that androgens block JNK activation
with concomitant inhibition of apoptosis in prostate cancer cells.
Androgen-induced JNK inhibition was independent of the JNK-
activating stimulus and, therefore, these data establish JNK itself as
a new focal point in the crosstalk between the AR and AP-1 signaling
pathways. We show, for the first time, that inhibition of JNK activity
by androgens occurs in a dose- and time-dependent manner and re-
quires functional AR and AR-dependent de novo gene expression.
Materials and Methods
Cell Lines and Cell Culture
Cell culture conditions and cell death induction have been de-
scribed previously [32]. Briefly, the human prostate cancer cell lines,
LNCaP, PC3, and DU145 were purchased from the American Type
Culture Collection and grown in RPMI 1640 medium supplemented
with 10% fetal bovine serum, 50 U/ml penicillin, 50 μg/ml strepto-
mycin, and 2 mM L-glutamine (all from BioWhittaker-Cambrex,
Verviers, Belgium) in a humidified atmosphere of 5% CO2 in air at
37°C. PC3-AR [34] and DU145-AR [35] cells were kindly provided
by Dr. M. Marcelli and Dr. el-N. Lalani, respectively. To deplete the
cells from androgens and lower the basal levels of activated JNK before
any of the treatments, the cells were kept in low-serum media: 2 days
in 2% charcoal-treated serum and 16 to 20 hours in 0.5% charcoal-
treated serum. All the treatments were done in 0.5% charcoal-treated
serum media. When indicated, cells were treated with the following
concentrations of the compounds: R1881 10−8 or 10−7 M, as indi-
cated (unless indicated differently, R1881 treatments are for 40 hours
before the addition of TPA or TG, or UV irradiation), TPA 5 ng/ml,
TG 100 nM, actinomycin D (ActD) 1 μg/ml, bicalutamide 10 to
100 μM. TPA, TG, and ActD were obtained from Sigma-Aldrich
(St. Louis, MO). Bicalutamide was obtained from Astra Zeneca
(Cheshire, UK).
Apoptosis and Viability Assays
Viability in LNCaP cells was assessed by trypan blue exclusion assay.
The cells were grown in six multiwell plates, harvested by trypsin-
ization at indicated times, and gently resuspended in a small volume
of PBS (100 to 150 μl/well). Ten microliters of cell suspension was
mixed with 10 μl of trypan blue (Sigma-Aldrich) previously diluted
1:1 with PBS. After 1 minute, cells were examined under the micro-
scope for nonviable cells, indicated by trypan blue uptake. A mini-
mum of 300 cells were counted for each well. Each experiment
was done in triplicates and was repeated at least three times. The per-
centage of nonviable cells was expressed per 100 of the total cells
(mean ± SD).
Apoptosis incidence was assessed by 4′,6-diamidino-2-phenylindole
(DAPI) staining and the terminal deoxynucleotidyl transferase–
mediated nick-end labeling (TUNEL) assay. For the detection of
fragmented nuclei, cells were grown on coverslips and analyzed by
fluorescence microscopy after DAPI staining. At least five areas and
a minimum of 1000 cells were counted for each plate. The experi-
ment was done in duplicate and repeated twice. Fragmented nuclei
incidence was expressed per 100 of the total cells (mean ± SD). Cell
apoptosis was characterized also by TUNEL assay, using the In Situ
Cell Detection Kit from Roche according to manufacturer’s instruc-
tions. Briefly, the cells grown onto coverslips were fixed with 4%
paraformaldehyde in PBS for 1 hour at room temperature. After
washing three times with PBS, the cells were permeabilized with
0.1% Triton X-100 in 0.1% sodium citrate for 10 minutes on ice.
Cells were then stained for the TUNEL assay, and green fluorescent
apoptotic bodies were visualized under a fluorescence microscope
(Zeiss Axioplan2 fluorescence microscope). For the visualization of
all the cells, a counterstaining with DAPI was performed. For statis-
tical analysis, at least five areas and a minimum of 1000 cells were
counted for each slide. The experiment was done in duplicate and
repeated twice. The number of TUNEL-positive cells was expressed
per 100 of the total cells (mean ± SD).
Western Analysis
Western analyses were performed as described previously [32].
Whole-cell extracts were prepared by lysing the cells in WCB
[20 mM Hepes (pH 7.7), 300 mM NaCl, 0.2 mM EDTA, 0.1%
Triton X-100, 1.5 mM MgCl2, 0.5 mM DTT, 20 mM β-glycerol
phosphate, 0.1 mM sodium orthovanadate, 2 μg/ml leupeptin,
0.5 mM PMSF] at 4°C for 2 hours. Protein extracts were resolved in
SDS-PAGE gels and transferred to polyvinylidene fluoride membranes.
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After blocking, the membranes were incubated overnight at 4°C
with the primary antibody in Tris-buffered saline–0.1% Tween
(TBST) containing 5% BSA. The membranes were then incubated
with the corresponding secondary antibody in TBST-5% nonfat
milk for 1 hour at room temperature and the immunoreactive bands
were visualized using the enhanced chemiluminescence detection
system (Amersham Biosciences, Buckinghamshire, UK). Antibodies
against total JNK and phospho-JNK were obtained from Cell Sig-
naling and used at 1:500 dilution. PSA and AR antibodies were
obtained from Santa Cruz Biotechnologies (Santa Cruz, CA) and
used at 1:300 and 1:500 dilutions, respectively. α-Tubulin antibody
was purchased from Sigma-Aldrich and used at 1:5000 dilution.
Kinase Assays
Whole-cell extracts were obtained as described above for Western
analysis. Solid-phase kinase assays were performed using glutathione
S-transferase (GST)-cJun (1-79) as substrate, as described previously
[32]. Briefly, 30 μg (for UV-treated cells) or 200 μg (for TG-
and TPA-treated cells) of the protein samples were incubated with
10 μg of GST-cJun fusion protein as substrate in binding buffer
(20 mM Hepes, 75 mM NaCl, 2.5 mM MgCl2, 0.1 mM EDTA,
0.05% Triton X-100, 0.5 mM DTT, 20 mM glycerol phosphate,
0.1 mM sodium orthovanadate, 2 μg/ml leupeptin, 100 μg/ml
PMSF) 3 hours at 4°C; the beads were washed three times and re-
suspended in 30 μl of kinase buffer [20 mM Tris-HCl (pH 7.5),
5 mM MgCl2, 0.5 mM DTT, 150 mM KCl, and 10 μM ATP]
and incubated for 20 minutes at 30°C in the presence of 5 μCi of
[γ-32P]ATP. After size fractionation on a 12% SDS-PAGE, bands
were visualized and quantified using phosphoimager analysis.
Immunofluorescence
Immunofluorescence analysis was performed as described previ-
ously, with minor modifications [36]. Briefly, LNCaP cells grown
on coverslips were fixed with methanol for 10 minutes at −20°C, per-
meabilized with 0.2% Triton X-100 in TBS and blocked in 5% BSA
in TBS-0.1% Triton X-100. Phospho-JNK and total JNK primary
antibodies were used overnight at 4°C at 1:50 dilution in TBS contain-
ing 3% BSA. The secondary antibody was conjugated to Alexa Fluor
594-Red. For the visualization of the nuclei, counterstaining with
DAPI was performed. The slides were analyzed using confocal laser
microscopy (Olympus Fluo View 1000, Olympus Europa GmbH,
Hamburg, Germany) and representative images were captured.
Phosphatase Activity
Phosphatase assays were performed on intact cells. The cells were
washed with buffer A (pH 7.8) (5.5 mM glucose, 136 mM NaCl,
2.6 mM KCl, 20 mM Hepes, 10 mM tricine). For phosphatase ac-
tivity reaction, the same number of cells was resuspended in 0.3 ml
of buffer A containing 5 mM pNPP (Sigma) and 1 mMMgCl2. After
60 minutes of incubation at 37°C, the reaction was stopped by addi-
tion of NaOH to a final concentration of 0.02 M. The amount of
pNP released from pNPP, reflecting phosphatase activity, was mea-
sured at 405 nm (protocol adapted from Ref. [37]).
Small Interfering RNA–Mediated Knockdown
of AR Expression
A previously described small interfering RNA (siRNA) targeting AR
[38] was selected to specifically knock down AR expression (siAR sense:
CUGGGAAAGUCAAGCCCAUTT, purchased from Dharmacon,
Lafayette, CO). LNCaP cells were transfected with siAR (200 nM)
using Oligofectamine (Invitrogen, Carlsbad, CA) according to manu-
facturer’s instructions. The transfections were performed in triplicate
and pools of the transfected cells were used for protein extraction
and western analysis. siRNA targeting the luciferase gene (siLuc) was
used as a negative control (Qiagen, Germantown, MD).
Statistics
Statistical analyses were performed using Student’s t test. Values of
P < .05 were considered significant.
Results
R1881 Protects LNCaP Cells from TPA- and
TG-induced Apoptosis
To study the effect of androgens in apoptosis of prostate cancer
cells, we used two previously established models of apoptosis: TG
and TPA treatments of the androgen-responsive prostate cancer cell
line LNCaP cells [28,31,32]. As we previously reported, the treat-
ment of LNCaP cells with these agents induces apoptosis that signif-
icantly increases after 12 and 36 hours for TPA and TG, respectively
[32]. To assess the possible effect of androgens in apoptosis induced
by these agents, we analyzed the time periods of 36 to 48 hours for
TG and 12 to 24 hours for TPA, which correspond to the times dur-
ing which rate of apoptosis induced by these agents starts.
We first analyzed the viability of LNCaP cells that were either left
untreated or pretreated with R1881 for 40 hours, before their ex-
posure to TG or TPA. As shown in Figure 1A, R1881 treatment
decreased LNCaP cell death induced by both TG and TPA by ap-
proximately 50%. This increase in cell viability in the presence of
R1881 was not due to a change in cell growth but to a decrease in
cell death, because under these experimental conditions (low serum)
R1881 did not affect cell proliferation (data not shown).
To study the protective effect of androgens on cell death in more
detail, we specifically determined the extent of apoptosis under these
conditions. First, nuclear morphology was assessed for features of
apoptosis after DAPI staining and examination of the nuclei by fluo-
rescence microscopy (data not shown). Apoptosis was further con-
firmed by the TUNEL assay, which detects cells undergoing DNA
fragmentation. For both TG and TPA, androgen pretreatment caused
a strong decrease in apoptosis incidence compared to the cells treated
with TG or TPA alone, reaching 65% to 70% lower levels of apop-
tosis in the presence of R1881 for TG and at least 50% in TPA-treated
cells (Figure 1, B and C ). The low basal levels of apoptosis induced by
the culturing conditions in the absence of TG or TPA were also inhib-
ited by androgens, suggesting that it is due to the activation of a similar
pathway (Figure 1C ). These data demonstrate that androgens protect
LNCaP cells from apoptosis induced by two different stimuli, TG and
TPA. Interestingly, these two compounds activate independent path-
ways; whereas TG increases the levels of cytosolic calcium [39], TPA
activates protein kinase C [40], pointing toward a general protective
effect of androgens.
Androgens Decrease TG- and TPA-induced JNK Activation
Previous studies showed that activation of JNK has a decisive role
in both TG- and TPA-induced apoptosis of LNCaP cells. Not only is
there a good correlation between the onset of apoptosis and the sus-
tained activation of JNK in these cells, but also specific inhibition of
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JNK activity blocked apoptosis induced by both agents [32,33]. We
therefore assessed whether the molecular mechanisms underlying the
antiapoptotic effect of R1881 involved alterations in the JNK path-
way itself. To this end, LNCaP cells were treated with R1881 before
the addition of TG or TPA, and JNK activation was analyzed at the
time points that correlate with the onset of apoptosis. The use of an
antibody that detects specifically the phosphorylated form of JNK al-
lowed us to check JNK activation by Western analysis. Consistent with
previous data [32], in response to TG and TPA treatments JNK path-
way was activated in a biphasic pattern, with an initial increase up to
6 hours for both agents and a second, more prolonged increase after
36 and 12 hours for TG and TPA, respectively (Figure 2, A and B). In
contrast, in R1881-treated LNCaP cells, JNK activation was abrogated
to near completion at 6 hours and significantly decreased at later time
Figure 1. Protective effect of androgens on TG- and TPA-induced cell death. LNCaP cells were grown on six-well plates. After a star-
vation period of 3 days, the cells were incubated with R1881 (10−7 M) for 40 hours followed by TG (100 nM), TPA (5 ng/ml), or vehicle for
the indicated times. (A) Cell death was scored at the indicated times by trypan blue exclusion assay as described in Materials and
Methods and quantified as a percentage of the total cell counts. Under these experimental conditions, significant differences were
observed between the levels of cell death of cells that were treated with R1881 and those of nontreated ones. For the statistical analysis,
at least three experiments were used. (*P < .01; **P < .001). (B) Microscope images of TUNEL assay on LNCaP cells at indicated times
after TG and TPA addition. The TUNEL-positive cells (those undergoing apoptosis) appear as green-fluorescent dots (examples indicated
by the arrows in the inset). (C) Quantification of the TUNEL results presented in (B), represented as the percentage of TUNEL-positive
cells. The columns represent the mean of two independent experiments done in duplicate. In each experiment, an average of 2000 cells
was scored. Bars represent the standard deviation.
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points, without any alteration in total JNK levels (Figure 2, A and B).
In both cases, the decrease in JNK phosphorylation was accompanied
by a decrease in JNK activity as shown in the solid-phase kinase assays
using GST-c-Jun as a substrate (Figure 2, C and D).
Taken together, these results indicate that the antiapoptotic action
of androgens in the prostate cancer cell line LNCaP cells may be me-
diated through the inhibition of the JNK pathway.
Androgens Inhibit UV-Induced Apoptosis of LNCaP Cells
To further study the role of R1881 in the regulation of JNK path-
way and apoptosis in LNCaP cells, we assessed the effect of andro-
gens on JNK activation and apoptosis induced by UV irradiation, a
well-known activator of JNK, with concomitant apoptosis in differ-
ent cell lines [14,41,42]. In LNCaP cells, UV irradiation induced
strong activation of JNK, reaching maximal levels by 30 minutes
after UV exposure. Pretreatment with R1881 before UV irradiation
caused a dramatic block of UV-induced JNK phosphorylation (Fig-
ure 3A). Interestingly, although UV is a more potent activator of
JNK than TG or TPA, the inhibition caused by R1881 treatment
was stronger in UV-treated cells blocking JNK activation by >90%.
We then assessed whether the inhibition of UV-induced JNK ac-
tivation observed in R1881-treated LNCaP cells correlates with a
decrease in apoptosis. Nuclear fragmentation analysis showed that
apoptosis of LNCaP cells started 6 hours after UV irradiation (Fig-
ure 3B). In parallel with the observed inhibition of UV-induced JNK
activation, androgen treatment also blocked UV-induced apoptosis
(Figure 3B).
Androgen-dependent inhibition of JNK activation and concomitant
apoptosis induced by UV supports our hypothesis of a general action
of androgens on apoptosis in prostate cancer cells, regardless of the
factor that triggers the apoptotic process. Consistent with this, the
phosphatase inhibitor, okadaic acid, which causes apoptosis of LNCaP
cells, also induces JNK activation. Both JNK activation and apoptosis
were reduced by androgens (Ref. [43] and data not shown).
The simultaneous decrease of JNK activation and apoptosis induced
by all four agents—TG, TPA, UV, and okadaic acid—by androgens
suggests that JNK is the common juncture of all these pathways where
androgens elicit their effect.
Androgens Inhibit JNK Activation in a Dose- and
Time-Dependent Manner
To further analyze the R1881-dependent inhibition of JNK activa-
tion, a time course study was performed. LNCaP cells were treated
with R1881 for increasing times and then irradiated with UV. In
all cases, to allow maximal activation of JNK, the cells were incubated
for 30 minutes after UV irradiation before being harvested. As shown
in Figure 3C, R1881 treatment shorter than 12 hours did not cause
any significant decrease in JNK activation upon UV irradiation,
whereas 24-hour R1881 treatment blocked JNK phosphorylation by
approximately 80%. This decrease became even more striking when
the time of exposure to R1881 was increased, causing a nearly com-
plete block of JNK activation after 48 hours treatment. This suppres-
sion of JNK phosphorylation was not due to a decrease in total JNK
protein (Figure 3C ). To our knowledge, this is the strongest inhibition
of JNK activation described to date by a soluble agent.
We also assessed whether R1881-induced inhibition of UV-dependent
JNK activation was dose dependent. Treatment of LNCaP cells with in-
creasing concentrations of R1881 caused a progressive decrease in JNK
activation with a nearly complete inhibition at 10−7 M (Figure 3D).
In summary, our data indicate that androgens inhibit UV-induced
JNK activation in both a dose- and a time-dependent manner in
LNCaP cells.
Previous studies have demonstrated that another member of the
nuclear receptor family, the GR, once activated by its ligand, blocks
Figure 2. R1881 treatment inhibits TG- and TPA-induced JNK activation. LNCaP cells were plated in 10-cm plates at a density of 1 ×
106 cells per plate and incubated in androgen-depleted low-serum media for 3 days before the treatment with R1881 (10−7 M) for
40 hours. After R1881 treatment, TG (100 nM) or TPA (5 ng/ml) was then added. At the indicated times the cells were harvested and
whole-cell extracts prepared. Cell extracts (200 μg) were subjected to Western analysis, using either anti-phospho-JNK (pJNK) or total
JNK (JNK) antibodies. (A, B) Western analysis of phosphorylated and total JNK in cell extracts from TG (A) or TPA (B) treatments. As a
loading control, a nonspecific band that migrated at 40 kDa was used. (C, D) JNK activity demonstrated by solid-phase kinase assay (KA)
using 200 μg of whole-cell extract from cultures treated with TG (C) and TPA (D). The lower panel (BB) shows the Coomassie blue
staining of the gel for loading control. The arrows indicate the specific bands.
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JNK activation by direct binding to inactive JNK, blocking its phos-
phorylation and simultaneously inducing nuclear translocation of in-
active JNK [27,44,45]. Although the time required for the hormonal
treatment to block JNK activation is significantly different (30 min-
utes for glucocorticoids and at least 36 hours for androgens), we
assessed whether androgen treatment causes an alteration on the cel-
lular distribution of JNK. To that end, we used confocal microscopy
to analyze the localization of both phosphorylated and total JNK
after UV irradiation in the presence or absence of R1881 in LNCaP
cells. As is well established [15,46], UV irradiation induced JNK
phosphorylation and its translocation to the nucleus (Figure 3E ).
Consistent with the Western analysis results presented above, an-
drogen treatment of LNCaP cells blocked the nuclear accumula-
tion of phosphorylated JNK (Figure 3E ). In contrast, there was no
significant alteration in total JNK levels or its cellular distribution
in androgen-treated cells when compared with control cells (Fig-
ure 3E ). These data, coupled to the significantly different time re-
quirements for inhibition of JNK by glucocorticoids compared
Figure 3. R1881 inhibits UV-induced JNK activation and apoptosis. (A) LNCaP cells were plated at a density of 1 × 106 cells per plate on
10-cm plates. After the starvation period, the cells were either left untreated or treated with R1881 (10−7 M) for 40 hours before UV
irradiation (2 J/cm2 for 5 seconds). At the indicated times after UV irradiation, the cells were harvested and whole-cell extracts were
prepared. Extracts (50 μg) were subjected to Western analyses with total JNK (JNK)- and phosphorylated JNK (pJNK)-specific antibodies.
Blots were also probed with an α-tubulin antiserum for loading control. (B) Quantification of apoptosis incidence in LNCaP cells 6 and
10 hours after UV exposure. The cells were grown on coverslips, either kept untreated or treated with R1881 for 40 hours before ex-
posure to UV light. Apoptotic cells, indicated by fragmented nuclei, were scored after DAPI staining. The data shown are the mean of
two independent experiments done in duplicate. An average of 2000 cells was scored in each experiment. (C) Time course of R1881
treatment of LNCaP cells before UV exposure. After UV irradiation, cells were incubated at 37°C for 30 minutes and harvested, and
whole-cell extracts were prepared. R1881-treated samples were done in duplicate. Extracts (50 μg) were resolved on SDS-PAGE and
subjected to Western analysis with JNK and pJNK antisera. Blots were also probed with an α-tubulin antiserum for loading control. (D)
LNCaP cells were treated for 40 hours with increasing concentrations of R1881 before UV irradiation. Thirty minutes after UV irradiation,
whole-cell extracts were prepared and subjected to Western analysis as described above. (E) LNCaP cells plated onto coverslips were
kept in charcoal-treated low-serum medium for 3 days. The cells were then either left untreated or treated with R1881 (10−7 M) for
40 hours and exposed to UV light as described above. After fixation with methanol, immunofluorescence analysis was carried out using
pJNK and JNK antisera as described in Materials and Methods. Counterstaining with DAPI is shown in the smaller panels. The data
presented are representative of two independent experiments done in duplicate.
Neoplasia Vol. 10, No. 5, 2008 Inhibition of JNK Activation by Androgens Lorenzo and Saatcioglu 423
with androgens, indicate that androgen-dependent inhibition of JNK
activation occurs through a different mechanism than that previously
described for glucocorticoids.
Androgen-Induced Block of JNK Activation Requires a
Functional Androgen Receptor
That inhibition of JNK activation by androgens is dose- and time-
dependent suggested a direct involvement of AR in this action. To
verify the involvement of AR in this process, we first assessed the
possible effect of R1881 on JNK activation in PC3 and DU145 cells,
two prostate cancer cell lines that do not express functional AR
[47,48]. PC3 and DU145 cells were either left untreated or pre-
treated with R1881 for 40 hours and were then exposed to UV irra-
diation and JNK activity was determined. As shown in Figure 4, A
and B, in neither of these two cell lines did R1881 have an effect on
UV-induced JNK activation. These data indicate that a functional
AR signaling pathway is required for the androgen-induced inhibi-
tion of JNK activation. Surprisingly, stable reexpression of AR in
both PC3 and DU145 cells did not restore the ability of androgens
to inhibit JNK activation (Figure 4, C and D). This could be be-
cause expression of AR does not completely reestablish the normal
androgen-signaling pathway and that other factors involved in andro-
gen signaling may be missing in these cells. Consistent with this, a
recent report [49] showed that both DU145 and PC3 cells do indeed
express low levels of AR; however, in neither of them can androgen
stimulate transcription of an AR-responsive reporter.
To further assess the possible involvement of AR in R1881-mediated
inhibition of JNK, we used two different approaches to specifically
inhibit AR-dependent action. We first used bicalutamide [50], a
compound widely used as a specific antagonist of AR in LNCaP
cells, as well as in the clinic [51,52]. LNCaP cells were treated with
increasing concentrations of bicalutamide under conditions where
JNK activation is inhibited by androgen treatment as presented
above. The decrease in the AR-target gene PSA (prostate-specific
antigen) confirmed the inhibition of AR-dependent transcription
in response to bicalutamide treatment (Figure 5A). This decrease
in PSA was accompanied by a reduction in androgen-induced inhi-
bition of JNK activation (Figure 5A), suggesting that AR is involved
in this process.
As a second approach to inhibit AR, we used siRNA to specifically
knock down AR before R1881 treatment of LNCaP cells. We used a
siRNA that was recently shown to be effective in knocking down AR
expression in LNCaP cells [38]. As can be seen in Figure 5B, 4 days
after siAR transfection AR levels were largely diminished compared
to control cells (in both untransfected and siLuc transfected cells).
The specific decrease in AR levels correlated with a block of R1881-
dependent JNK inhibition. These data, together with the results ob-
tained with the bicalutamide presented above (Figure 5A), show that
AR is required for androgen-dependent inhibition of JNK activation.
Androgen Inhibition of JNK Activation Requires New
RNA Synthesis
The long R1881 treatment period (40 hours) that is necessary to
optimally block JNK activation and the involvement of AR in this
process indicated that androgen action may require new gene ex-
pression. To assess this possibility, LNCaP cells were pretreated with
the RNA synthesis inhibitor ActD before androgen treatment and
the effect of R1881 on JNK activation was assessed by Western
Figure 4. R1881 treatment has no effect on the androgen-insensitive PC3 and DU145 cells. PC3 (A) and DU145 cells (B) were treated
with R1881 (10−7 M) for 40 hours before exposure to UV (2 J/cm2 for 5 seconds). After UV induction, the cells were incubated at 37°C
and harvested at the indicated times. Whole-cell lysates (75 μg) were subjected to Western analysis using phospho-JNK (pJNK) and total
JNK (JNK) antisera as described in Materials and Methods. Blots were also probed with an α-tubulin antiserum for loading control. (C)
Wild-type PC3 cells (PC3-wt) and PC3 cells stably expressing AR (PC3-AR) were treated with R1881, irradiated with UV, and analyzed as
in (A) with a harvest time of 30 minutes. (D) The same experiment as in (C) was performed with DU145-wt and DU145-AR cells.
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analysis as described above. As shown in Figure 5C, pretreatment of
LNCaP cells with ActD blocked androgen-induced inhibition of
JNK phosphorylation without affecting the levels of total JNK pro-
tein, indicating that R1881 inhibition of JNK activation requires
new gene expression.
Because different signaling pathways can interact with each other,
we next analyzed whether the effect of R1881 on JNK activity re-
quired other major signaling pathways. To that end, we first studied
the possible involvement of the other major MAPK pathways. LNCaP
cells were pretreated with either SB203580, an inhibitor of the p38
pathway, or PD98059, an inhibitor of the ERK pathway, before
treatment with R1881. Neither inhibitor had any effect on androgen-
induced inhibition of JNK phosphorylation (data not shown). Consistent
with this, there was no significant increase in p38 or ERK phosphoryla-
tion upon androgen treatment (data not shown).
We next assessed the possible involvement of the phosphatidylino-
sitol 3′-kinase (PI3K) pathway, which has been implicated in the
survival of LNCaP cells under acute androgen deprivation [53].
We did not detect any increase in activated Akt levels in androgen-
treated cells (data not shown). Moreover, wortmannin, an inhibitor
of PI3K, had no effect on R1881 action on JNK activation (data not
shown). Taken together, these data suggest that the inhibitory effect
of R1881 on JNK activity does not require the activation of any of
these related pathways.
We next assessed the known upstream components of the JNK
pathway. MKK4 and MKK7 are two of the MKKs that are most fre-
quently involved in JNK activation [15,54]. Analysis of UV-activated
MKK4 and MKK7 levels in response to androgens revealed no sig-
nificant effects (data not shown). These data suggest that the inhibi-
tory action of androgens takes place at the JNK level itself.
It is known that JNK activation is not only regulated by its phos-
phorylation by upstream kinases of the pathway, but also by its de-
phosphorylation by phosphatases (for a review, see Ref. [16]). To
assess whether there were any changes in phosphatase activity in re-
sponse to androgens, we analyzed global phosphatase activity in LNCaP
cells after UV irradiation in the presence or absence of R1881. There
was a significant increase in phosphatase activity in R1881-treated cells
when compared with their nontreated counterparts, both in nontreated
cells and in UV-irradiated cells (Figure 5D). Supporting these results,
the dephosphorylation rate of JNK upon ATP depletion is increased in
the presence of androgens, suggesting that androgens facilitate JNK de-
phosphorylation (data not shown).
Figure 5. R1881 inhibition of JNK activation requires AR-dependent transcriptional activation. (A) LNCaP cells were plated on 10-cm
plates and incubated in low-serum media for 3 days. One hour before the addition of R1881 (10−8 M) the cells were treated with in-
creasing concentrations of the androgen antagonist bicalutamide (Bical). After 40 hours of androgen treatment, the cells were UV irra-
diated and incubated at 37°C for 30 minutes before being harvested. Whole-cell lysates (100 μg) were subjected to Western analysis for
JNK expression (JNK), JNK activation (pJNK), and PSA expression. Blots were also probed with an α-tubulin antiserum for loading con-
trol. (B) LNCaP cells were plated on six multiwell plates and incubated in 2% charcoal-treated serum media for 2 days before their
transfection with siAR. R1881 treatment was started 36 hours after siAR transfection, After 40 hours in the presence of R1881, the
cells were UV irradiated and incubated at 37°C for 30 minutes before being harvested. siRNA transfections were performed in triplicate
and a pool of cells from three wells was used for protein extraction. Whole-cell lysates (75 μg) were subjected to Western analysis using
AR, phospho-JNK (pJNK), and total JNK (JNK) antisera as described in Materials and Methods. Blots were also probed with an α-tubulin
antiserum for loading control. (C) LNCaP cells incubated in androgen-depleted low serum medium for 3 days were then pretreated with
ActD (1 μg/ml) for 1 h before the addition of R1881 (10−7 M). After 40 hours, the cells were exposed to UV (2 J/cm2 for 5 seconds) and
incubated at 37°C for 30 minutes before being harvested. Whole-cell extracts (50 μg) were resolved by SDS-PAGE and subjected to
Western analysis using pJNK and JNK antibodies. Blots were also probed with a GAPDH antiserum for loading control. (D) LNCaP cells
were either kept untreated or treated with R1881 (10−7 M) for 40 hours before UV irradiation. Phosphatase activity in intact cells was
measured by the amount of pNP released from pNPP as described in Material and Methods.
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In summary, these data suggest that androgens increase the phos-
phatase activity in LNCaP cells, which leads to inactivation of JNK.
Further studies are required to identify the phosphatase(s) that can
account for R1881-dependent inhibition of JNK activation.
Discussion
The mechanisms by which androgens elicit their pro-proliferative
and antiapoptotic effects in the normal prostate and in human pros-
tate cancer cells are largely unknown. This knowledge is necessary
for the development of new and more effective therapeutic strategies
for prostate cancer treatment. Here, we have provided evidence that
the antiapoptotic action of androgens in prostate cancer cells, at least
in part, is due to inhibition of JNK signaling through a mechanism
that requires AR-dependent new gene expression. The requirement
of AR in this process was demonstrated not only by the loss of JNK
activation and concomitant apoptosis induced by androgens, but
also by the restoration of JNK activity both in the presence of the
AR antagonist bicalutamide as well as by specific knockdown of
AR by siRNA.
It is well known that the depletion of androgens induces apop-
tosis in the normal prostate as well as in prostate cancer in its begin-
ning stages, causing rapid regression of the gland/tumor [2–4,55].
However, after some time, prostate cancer recurs in an androgen-
independent form (reviewed in Refs. [5,7]). It is now believed that
in this later stage, despite the low levels of androgens, AR remains
activated (reviewed in Refs. [55–57]). This is supported by the fact
that knocking down AR expression had a more pronounced effect on
AR-induced transcription and cell growth/apoptosis than androgen
depletion itself [58,59]. It is therefore important to know the molec-
ular mechanisms of antiapoptotic action mediated by AR even in an
androgen-depleted environment. Thus, our identification of the apop-
totic JNK pathway as a target for AR action is significant in this regard.
However, this specific action of AR cannot account for the prosurvival
actions of androgens in normal cells that are not under stress, where
there is no activation of the JNK pathway.
The role of JNK pathway activation in apoptosis is known to be
highly context dependent [14]. The complexity of JNK signaling is
influenced by several factors: the different and overlapping activities
of JNK isoforms, the multitude of upstream activating kinases, the
different scaffold molecules, and the variety of compartment-defined
substrates [41,60,61]. We and others have demonstrated that JNK
activation is required for apoptosis of prostate cancer cells in response
to both TG and TPA [32,33]. The inhibition of JNK activation,
either by expression of the JNK binding domain of JNK interacting
protein-1 or by treatment with the JNK-specific inhibitor SP600125,
caused a decrease in apoptosis, confirming the important role of the
JNK pathway in this process [32,33].
Previous studies that focused on the role of AR-JNK pathway in-
teractions in modulating apoptosis in LNCaP cells resulted in con-
flicting findings. Whereas in one study 2-methoxyestradiol–induced
apoptosis is inhibited by androgens that correlated with a decrease in
JNK activation [62], another study found that N-(4-hydroxyphenyl)
retinamide–induced apoptosis was enhanced by androgens that cor-
related with activation of the JNK pathway [63]. Our data from all
four inducers that we tested (TG, TPA, UV, and okadaic acid) sup-
port the results from the first study [62], suggesting that androgen
treatment inhibits JNK activation and concomitant apoptosis in
LNCaP cells regardless of the agent that triggers this apoptotic pro-
cess. This places JNK at a key junction point for apoptosis in prostate
cancer cells that is targeted by androgens. Consistent with JNK as
a common focal point, we did not observe significant changes in
the activity of the JNK upstream kinases, MKK4 and MKK7 (un-
published data). N-(4-Hydroxyphenyl)retinamide–induced apoptosis
and its augmentation by androgens is a special case that may involve
unique pathways that affect JNK signaling. Because our study, which
was based on the reexpression of AR in DU145 and PC3 cells, was
not enough to completely reestablish AR pathway in these two cell
lines, further studies using other androgen-responsive prostate cancer
cells similar to LNCaP cells will be useful to confirm this general
inhibitory action of androgens.
The crosstalk between JNK and some other members of the nu-
clear receptor superfamily, but not AR, has previously been described
[25,44,64,65]. For example, ligand-activated GR can physically in-
teract with inactive JNK; this interaction inhibits JNK phosphoryla-
tion and induces its nuclear translocation [27,45,64]. These events
occur rapidly in a manner that is independent of new gene tran-
scription. In contrast to GR and other nuclear receptors tested so
far [25,27,45], we have shown that inhibition of JNK phosphoryla-
tion by AR requires extended time (at least 36 hours), suggesting a
mechanism of action that is different than for other nuclear receptors
reported so far. This is supported by the fact that androgen-induced
inhibition of JNK requires new gene transcription, which is not re-
quired for GR-dependent inhibition of JNK.
The participation of AR-dependent new gene expression, and
therefore intermediate protein(s), in the inhibition of JNK activation
by androgens suggested that other signaling pathways may also be
involved in this crosstalk. However, ERK and p38 inhibitors had
no effect on androgen-induced inhibition of JNK phosphorylation;
consistently, there was no increase in the activity of these two path-
ways in response to androgen treatment, indicating that they are not
involved in this process. Another important signaling pathway that
could be relevant in this regard is the PI3K/protein kinase B pathway,
which is critical for cell survival in many cell types, including prostate
cancer cells (for a review, see Ref. [66]). However, we found no in-
crease in Akt activation in response to androgen in LNCaP cells, and
the PI3K inhibitor wortmannin did not have an effect on androgen-
dependent inhibition of JNK activation (unpublished data); there-
fore, activation of PI3K/protein kinase B pathway is not involved
in the inhibition of JNK phosphorylation by androgens in LNCaP
cells. Although these results suggest that androgen-induced inhibi-
tion of JNK activation occurs by direct modulation of the JNK path-
way, we cannot exclude the involvement of other signaling pathways
that we have not yet analyzed.
Sustained reactive oxygen species (ROS) accumulation can trigger
JNK activation through the inactivation of MAPK phosphatases
(MKPs) [67] suggesting that inhibition of ROS accumulation could
be responsible for the inhibition of JNK activation by androgens in
LNCaP cells. However, the analysis of ROS levels in LNCaP cells
showed that R1881 treatment induces an accumulation of ROS,
consistent with previously published data [68], that is not inhibited
under conditions where JNK activation is blocked by R1881 (data
not shown).
Phosphatases are another group of proteins that could mediate
the inhibitory effect of androgens on JNK activation. The increase
in the phosphatase activity that we observed in the presence of an-
drogens together with the faster dephosphorylation rate of JNK in
androgen-treated cells suggests the presence of phosphatase(s) among
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the intermediate protein(s) involved in androgen-mediated inhibi-
tion of JNK activation. Supporting the possible involvement of phos-
phatases in regulating apoptosis in prostate cancer, previous work
suggested that in human prostate tumors MKP-1 may inhibit apop-
tosis through the inhibition of the JNK pathway. These studies indi-
cated that MKP-1 was overexpressed in preinvasive prostate cancer
compared with normal prostate [69]. In addition, MKP-1 expression
was inversely correlated with the enzymatic activity of JNK-1, but
not that of ERK-1 [69]. Furthermore, in high-grade PIN lesions,
MKP-1 expression was inversely correlated with their apoptotic po-
tential [70]. Despite these interesting data with MKP-1, analyses of
the expression of the different dual-specificity phosphatases that have
been previously implicated in JNK dephosphorylation (DUSP1,
DUSP8, and DUSP10) did not reveal any clear regulation by an-
drogens that can account for the inhibition of UV-, TG-, or TPA-
dependent JNK activation (unpublished data). However, because we
demonstrated both an increase of phosphatase activity and a faster
dephosphorylation of JNK in androgen-treated cells, it is possible
that other member(s) of the rapidly growing DUSP family, or similar
phosphatases, may be involved and further experiments are in prog-
ress to assess this possibility.
Other JNK-interacting proteins may be involved as well, such as
GSTs that under normal conditions bind to and inhibit JNK [71,72].
Furthermore, overexpression of the scaffolding protein JIP1 can prevent
JNK activity by sequestering JNK [33]. It has also been demonstrated
that under certain conditions JIP proteins can also recruit DUSPs re-
sulting in enhanced dephosphorylation and inactivation of JNK [73].
Taking these data into account, regulation of expression and/or activity
of these proteins could be another possible mechanism that can ac-
count for the inhibitory action of androgens on JNK activity.
What is the significance of these results in human prostate cancer?
The identification of JNK as a focal point for AR-dependent inhibi-
tion of apoptosis in prostate cancer cells suggests that it may be useful
as a diagnostic or prognostic marker, as well as a new target for treat-
ment. Consistent with this central role of JNK, a preliminary analysis
suggests that JNK activation is downregulated with increasing grade
of human prostate cancer (unpublished data). These findings are con-
sistent with the data we present here suggesting that inhibition of JNK
activation, perhaps through AR-dependent activation of specific phos-
phatase/s or other JNK interacting proteins, is linked to a significant
decrease in apoptosis of prostate cancer cells. This could be the mecha-
nism, at least in part, of how the apoptotic potential of advanced pros-
tate cancers is inhibited where AR is known to be still activated.
Therefore, these data suggest that increasing JNK activity in prostate
cancer cells would reinstate their apoptotic potential and, consequently,
may have clinical use for controlling disease progression.
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